C B Mariani
Overview
Explore the profile of C B Mariani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
79
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
De Gaspari D, Siri C, Landi A, Cilia R, Bonetti A, Natuzzi F, et al.
J Neurol Neurosurg Psychiatry
. 2006 Mar;
77(4):450-3.
PMID: 16543520
Background: The clinical condition of advanced Parkinson's disease (PD) patients is often complicated by motor fluctuations and dyskinesias which are difficult to control with available oral medications. Objective: To compare...
2.
Zincone A, Landi A, Piolti R, Appollonio I, Mariani C, Pezzoli G, et al.
Neurol Sci
. 2001 Aug;
22(1):111-2.
PMID: 11487185
Deep brain stimulation (DBS) obtains good control of advanced PD symptoms. Chronic stimulation of Stn may alleviate rigidity, dyskinesia and tremor. Anatomical and functional intraoperative mapping are mandatory to obtain...
3.
Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani C, Pezzoli G
Mov Disord
. 2000 Sep;
15(5):986-9.
PMID: 11009210
Depression is a common finding in patients with Parkinson's disease (PD). Traditionally, depression has been treated with tricyclic antidepressants, which are often associated with undesirable side effects that may limit...
4.
Pezzoli G, Canesi M, Antonini A, Righini A, Perbellini L, Barichella M, et al.
Neurology
. 2000 Sep;
55(5):667-73.
PMID: 10980731
Background: Single cases of parkinsonism have been associated with hydrocarbon solvents. Objective: To determine whether exposure to hydrocarbon solvents is related to PD. Methods: Cohort study of 990 patients with...
5.
Canesi M, Antonini A, Mariani C, Tesei S, Zecchinelli A, Barichella M, et al.
J Neural Transm (Vienna)
. 1999 Dec;
106(9-10):925-9.
PMID: 10599874
Patients with Parkinson's disease (n = 68) switched from pergolide or bromocriptine to ropinirole overnight (dose equivalence ratios 1:6 and 10:6, respectively). The activities of daily living score for the...
6.
Pezzoli G, Antonini A, Barbieri S, Canesi M, Perbellini L, Zecchinelli A, et al.
Mov Disord
. 1995 May;
10(3):279-82.
PMID: 7651443
n-Hexane, similar hydrocarbons, and derivatives are common environmental pollutants and by-products of lipid peroxidation, and they may have a nigrotoxic effect like that of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. This report describes our second...
7.
Masotto C, Bisiani C, Camisasca C, Fusi R, Ricciardi S, Fonzi N, et al.
J Neural Transm Suppl
. 1995 Jan;
45:281-5.
PMID: 8748636
In order to investigate the effect of n-hexane and its metabolites on the Central Nervous System (CNS), we treated mice with n-hexane and 2,5-hexanedione (2,5-HD) by intraperitoneal (i.p.) administration. Gascromatographic...
8.
Pezzoli G, Canesi M, Pesenti A, Mariani C
J Neural Transm Suppl
. 1995 Jan;
45:203-12.
PMID: 8748627
In the past 15 years, clinical data of over 1,500 patients treated with pergolide mesylate have been published. Pergolide is a dopamine agonist with a potent stimulating effect on D2...
9.
Pezzoli G, Ricciardi S, Masotto C, Mariani C, Carenzi A
Brain Res
. 1990 Oct;
531(1-2):355-7.
PMID: 1705155
A case of human parkinsonism, due to n-hexane exposure, was recently described. On the basis of this observation, we treated mice and rats with n-hexane and its principle toxic metabolite...